Latest Hospitality News

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.

EBR Systems marked a pivotal transition in 2025 with FDA approval of its WiSE CRT System and the initiation of U.S. commercial implants, generating $1.6 million in revenue. Despite this progress, the company reported a net loss of $48.8 million and completed a significant capital raise to support ongoing growth.

OMG Group has appointed Food & Dairy Co as the first official distributor of its new matcha brands, opening access to over 2,000 cafes and restaurants in NSW and Queensland. This move marks a key step in OMG’s strategy to expand its health-focused beverage portfolio.

Clarity Pharmaceuticals has unveiled compelling Phase II trial results showing its Cu-SAR-bisPSMA PET imaging agent significantly improves detection of prostate cancer recurrence over the current standard. The data, presented at the 2026 European Association of Urology Congress and accepted by European Urology journal, mark a key milestone ahead of regulatory submissions.

Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.

InteliCare Holdings has appointed seasoned healthcare executive Angus Cameron as CEO to lead its transition from pilot projects to full-scale commercial deployment following a major aged care contract.

BlinkLab has completed onboarding its tenth and final clinical site for its pivotal FDA 510(k) trial of an AI-powered autism diagnostic aid, setting the stage for patient enrolment to begin this month.

EMVision Medical Devices has secured a $3.8 million R&D tax rebate and gained approval to claim rebates on overseas expenditures, strengthening its financial footing as it advances clinical trials for its neurodiagnostic device.

Vection Technologies has secured approximately $4 million in new orders for its Algho AI platform, spanning 10 diverse industry verticals and reinforcing its strong momentum following a record half-year performance.

OMG Group has launched two new matcha brands targeting both premium and mass-market consumers, supported by a five-year exclusive supply agreement for ceremonial-grade Japanese matcha. This move positions OMG to capitalise on the booming global matcha market through a vertically integrated strategy.

Patrys has initiated manufacturing and regulatory steps for RLS-2201, its injectable Quetiapine formulation targeting delirium, aiming for Phase 0 trials in the second half of 2026.

Orthocell has appointed LEDA Orthopaedics as the exclusive distributor for its Remplir™ nerve repair product in the UK, positioning itself for a rapid commercial launch pending regulatory approval.